ANZEMET TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

DOLASETRON MESYLATE

Disponible des:

SANOFI-AVENTIS CANADA INC

Codi ATC:

A04AA04

Designació comuna internacional (DCI):

DOLASETRON

Dosis:

100MG

formulario farmacéutico:

TABLET

Composición:

DOLASETRON MESYLATE 100MG

Vía de administración:

ORAL

Unidades en paquete:

15

tipo de receta:

Prescription

Área terapéutica:

5-HT3 RECEPTOR ANTAGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0132936002; AHFS:

Estat d'Autorització:

CANCELLED POST MARKET

Data d'autorització:

2014-04-21

Fitxa tècnica

PRODUCT MONOGRAPH
PR
ANZEMET
®
(DOLASETRON MESYLATE)
100 MG TABLET
ANTIEMETIC
(5-HT
3 RECEPTOR ANTAGONIST)
sanofi-aventis Canada Inc.
2150 St. Elzéar Blvd. West
Laval, Quebec H7L 4A8
Date of Revision:
July 5, 2012
SUBMISSION CONTROL NO.: 155815
s-a Version dated
Page 2 of 25
_ _
PRODUCT MONOGRAPH
PR
ANZEMET
®
(Dolasetron Mesylate)
100 mg Tablet
_ _
Antiemetic
(5-HT
3
receptor antagonist)
ACTION AND CLINICAL PHARMACOLOGY
Dolasetron and its active metabolite, hydrodolasetron (MDL 74156), are
selective 5-HT
3
receptor
antagonists shown not to have activity at other known serotonin
receptors and with low affinity for
dopamine receptors. The serotonin 5-HT
3
receptors are located on the nerve terminals of the vagus
in the periphery and centrally in the chemoreceptor trigger zone of
the area postrema. It is thought
that chemotherapeutic agents produce nausea and vomiting by releasing
serotonin from the
enterochromaffin cells of the small intestine, and that serotonin then
activates the 5-HT
3
receptors
located on vagal afferents to initiate the vomiting reflex.
In healthy volunteers (N=4), dolasetron mesylate in single intravenous
doses up to 5 mg/kg
produced
no
effect
on
pupil
size
or
meaningful
changes
in
EEG
tracings.
Results
from
neuropsychiatric tests revealed that dolasetron mesylate does not
alter mood or concentration.
Multiple daily doses of dolasetron have no effect on colonic transit
in humans. Dolasetron has no
effect on plasma prolactin concentrations.
EFFECTS ON ELECTROCARDIOGRAM
Acute, reversible, ECG changes (PR and QTc; QRS widening), caused by
dolasetron, have been
observed in controlled clinical trials. Dolasetron appears to prolong
both depolarization and
repolarization time. The magnitude and frequency of the ECG changes
increased with dose (related
to the peak plasma concentration of hydrodolasetron but not the parent
compound). These ECG
changes usually returned to baseline within 6 to 8 hours, but in some
patients have lasted 24 h or
longer. Dolasetron mesylate administration has little or no